Skip to main content
  • Pooled Analysis of Phase II Trials Shows Promise of Asundexian Safety in Patients with AF, Recent AMI or Stroke

    Efficacy, however, is in question after phase III trial in patients with atrial fibrillation was stopped for lack of efficacy vs. apixaban

    A pooled analysis of phase II trials of the Factor XIa inhibitor asundexian showed that it was associated with less bleeding than apixaban in patients with atrial fibrillation and similar bleeding to placebo in patients who recently experienced an acute myocardial infarction (AMI) or stroke.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details